Click Therapeutics granted FDA market authorization for digital migraine drug
Digital therapeutic company Click Therapeutics was granted FDA marketing authorization for its prescription digital therapeutic for the preventive treatment of episodic migraines. The de novo classification is for the company’s CT-132 offering, for which it received FDA Breakthrough Device Designation in 2022. CT-132 is intended for the preventive treatment of episodic migraines in patients 18…